2
项与 Allogeneic NK cell therapy(Institute of Hematology & Blood Diseases Hospital) 相关的临床试验Clinical Study on the Safety and Efficacy of QN-030a in Acute Myeloid Leukemia
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in relapse/refractory Acute Myeloid Leukemia (AML).
This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-030a in patients with r/r AML, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.
Clinical Study on the Safety and Efficacy of QN-030a in Acute Myeloid Leukemia With Minimal Residual Disease
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid Leukemia Minimal Residual Disease(AML MRD).
This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-020a in patients with AML MRD, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.
100 项与 Allogeneic NK cell therapy(Institute of Hematology & Blood Diseases Hospital) 相关的临床结果
100 项与 Allogeneic NK cell therapy(Institute of Hematology & Blood Diseases Hospital) 相关的转化医学
100 项与 Allogeneic NK cell therapy(Institute of Hematology & Blood Diseases Hospital) 相关的专利(医药)
100 项与 Allogeneic NK cell therapy(Institute of Hematology & Blood Diseases Hospital) 相关的药物交易